Spark Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash rent income
Depreciation and amortization expense
Loss on disposal of property and equipment
Acquired in-process research and development
Stock-based compensation expense
Impairment of acquired in-process research and development
Non-cash income tax benefit
Gain from sale of priority review voucher
Unrealized loss on equity investments
Non-cash interest income
Changes in operating assets and liabilities:
Inventory
Prepaid expenses and other assets
Trade and other receivables
Accounts payable and accrued expenses
Deferred rent
Deferred revenue
Other liabilities
Net cash used in operating activities
Cash flows from investing activities:
Proceeds from sale of priority review voucher
Payment for license agreement
Purchase of acquired in-process research and development
Payment for acquisition, net of cash acquired
Purchase of marketable securities
Proceeds from maturities of marketable securities
Purchase of property and equipment
Net cash (used in) provided by investing activities
Cash flows from financing activities:
Proceeds from issuance of Series A convertible preferred units
Proceeds from issuance of Series B convertible preferred stock, net
Financing costs
Proceeds from exercise of options
Purchase of treasury stock
Proceeds from issuance of common stock under ESPP
Proceeds from long-term debt
Payments on long-term debt
Net cash provided by financing activities
Effect of exchange rate changes on cash and cash equivalents
Cash and cash equivalents, end of year
Net cash provided by financing activities
Effect of exchange rate changes on cash and cash equivalents and restricted cash
Net (decrease) increase in cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash, beginning of year
Cash and cash equivalents and restricted cash, end of year
Supplemental disclosure of cash flow information:
Property and equipment purchases included in accounts payable and accrued expenses
Deferred financing costs included in accounts payable and accrued expenses
One Drexel Plaza lease cost included in other liabilities

Comments